Sinfonia Biotherapeutics readies its NeuRepair product SB0101 for clinical phase IIb studies in sciatica
The US Food and Drug Administration (FDA) has approved Sinfonia’s Investigational New Drug (IND) application for phase IIb studies in chronic sciatic pain with its lead compound SB0101. The Phase IIb trial builds on positive results obtained in a...
Sinfonia Biotherapeutics’ NeuRepair product SB0101 demonstrates excellent product characteristics
Sinfonia’s lead compound SB0101 for treatment of chronic sciatica is an injectable biologic that has demonstrated impressive pain lowering activities in clinical studies. In preparation for further clinical development, new stability data of the...
Sinfonia receives a collaborative grant from Michael J Fox Foundation for the development of a novel combinatorial precision gene therapy for Parkinson’s disease
MJFF grant_News release
New CSO appointed: Olof Larsson, PhD
The current member of the Sinfonia board of directors, Olof Larsson, is entering the operational role as the company’s CSO. Olof is replacing Johan Lundkvist who is continuing as COO. Olof’s prior experience as CSO for Eli Lilly Pain and Migraine...
Sinfonia welcomes new board members
Sinfonia_New board members
Sinfonia’s CEO Lars Wahlberg interviewed in Dagens Industri